Dr. Tahami is a clinician-scientist and senior executive in the global pharmaceutical industry bringing new and innovative medicines to patients from concept to approval and beyond by focusing on translating research outcomes to clinical practice. His industrial career spans across clinical, medical, and commercial leaderships and has been a strong advocate for new approaches to value in health and care. He has led diverse global and national teams in early- and late-stage product development to define, develop, and deliver robust scientific evidence of clinical and economic value to stakeholders (patients, payers, and providers) that support informed decision making and health policy. During his career, Dr. Tahami has developed, launched, and commercialized over twenty medicines in various therapeutic areas, including respiratory, cardiovascular, diabetes, infectious diseases (HIV and HCV), immunology, oncology, and neurology, including the industry-leading medicines in immuno-oncology—YERVOY® and OPDIVO®—and the blockbuster drugs NASONEX®, REMICADE®, SIMPONI®, and ELIQUIS®.
Dr. Tahami trained in medicine, clinical pharmacology, epidemiology and biostatistics. In addition to his diverse academic background, he has accumulated over twenty years of experience in clinical research in academia and pharmaceutical industry. His research interest spans several major areas of epidemiology driven by the interest in developing pragmatic solutions to real-world problems in pharmacometrics, pharmacoepidemiology, pharmacoeconomics, and health services research. Dr. Tahami has contributed to methods in the field, in particular relating to developing and validating algorithms in health services research to measure clinical outcomes, reducing the risk of bias and confounding in observational studies, and novel modeling approaches to estimate the survival and economic outcomes of immuno-oncology medicines.
